ABBV vs ESTA
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. ESTA: Establishment Labs is a medical technology company advancing women's health through its next-generation Motiva breast implant technology and aesthetic surgical solutions.
Side-by-side fundamentals
| Metric | ABBV | ESTA | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $264.96 | $72.67 | |
| Market cap as of 2026-08-24 | $468.2B | $2.2B | |
| P/E as of 2026-08-24 | 70.24 | n/a | |
| PEG as of 2026-08-24 | 6.59 | n/a | |
| Net margin as of 2026-08-24 | +9.8% | -19.1% | ABBV higher |
| Gross margin as of 2026-08-24 | +72.8% | +70.1% | ABBV higher |
| Operating margin as of 2026-08-24 | +26.2% | -12.4% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | -225.9% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | -12.7% | ABBV higher |
| Debt / equity as of 2026-08-24 | 49.22 | 17.58 | ESTA lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | +34.9% | ESTA higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +9.3% | ESTA higher |
| Dividend yield as of 2026-08-24 | +4.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.22 | 1.07 | |
| 1-year return as of 2026-08-21 close | +26.5% | +81.7% | ESTA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.